Effect of intensiveversus standard blood pressure treatment according to baseline prediabetes status: A post hoc analysis of a randomized trial

Diabetes Care

Volumn 40, Issue 10, 2017, Pages 1401-1408

  Bress, Adam P ^a,b   King, Jordan B ^c   Kreider, Kathryn E ^d   Beddhu, Srinivasan ^a   Simmons, Debra L ^a,b   Cheung, Alfred K ^a   Zhang, Yingying ^a   Doumas, Michael ^e   Nord, John ^a   Sweeney, Mary Ellen ^f   Taylor, Addison A ^g   Herring, Charles ^h   Kostis, William J ⁱ   Powell, James ^j   Rastogi, Anjay ^k   Roumie, Christianne L ^l   Wiggers, Alan ^m   Williams, Jonathan S ⁿ   Yunis, Reem ^o   Zias, Athena ^b,p   Evans, Greg W ^q   Greene, Tom ^a   Rocco, Michael V ^q   Cushman, William C ^r   Reboussin, David M ^q   Feinglos, Mark N ^s   Papademetriou, Vasilios ^e   more..

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c KAISER PERMANENTE   (United States)

^d DUKE UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h CAMPBELL UNIVERSITY   (United States)

ⁱ ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^j EAST CAROLINA UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^m CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o STANFORD UNIVERSITY   (United States)

^p STONY BROOK UNIVERSITY   (United States)

^q WAKE FOREST SCHOOL OF MEDICINE   (United States)

^r VETERANS AFFAIRS MEDICAL CENTER   (United States)

^s DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; AGED; ALL CAUSE MORTALITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 85037104816     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0885     Document Type: Article

References (23)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444
2. Qiu M, Shen W, Song X, et al. Effects of prediabetes mellitus alone or plus hypertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: Longitudinal study. Hypertension 2015;65:525-530
3. Wright JT Jr, Williamson JD, Whelton PK, et al.; SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373:2103-2116
4. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
5. AmbrosiusWT, Sink KM, Foy CG, et al.; SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014;11:532-546
6. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann InternMed 1999;130:461-470
7. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008;117:743-753
8. Systolic Blood Pressure Intervention Trial (SPRINT) protocol version 4.0 [article online], 2012. Available from https://www.sprinttrial .org/public/Protocol-Current.pdf. Accessed 18 October 2015
9. Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effectmodification and interaction. Int J Epidemiol 2012;41:514-520
10. Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med 2008;121:519-524
11. Shaw JE, Zimmet PZ, Hodge AM, et al. Impaired fasting glucose: How low should it go? Diabetes Care 2000;23:34-39
12. Charles MA, Fontbonne A, Thibult N, Warnet J-M, Rosselin GE, Eschwege E. Risk factors for NIDDM in white population. Paris prospective study. Diabetes 1991;40:796-799
13. Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004;23:2509- 2525
14. Royston P, Sauerbrei W. Interaction of treatmentwith a continuous variable: Simulation study of significance level for several methods of analysis. Stat Med 2013;32:3788-3803
15. Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: The ACCORD randomized trial. Diabetes Care 2014; 37:1721-1728
16. Perkovic V, Rodgers A. Redefining bloodpressure targets-SPRINT starts the marathon. N Engl J Med 2015;373:2175-2178
17. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and metaanalysis. Lancet 2016;387:957-967
18. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. Lancet 2016;387:435-443
19. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: A systematic review and network meta-analysis. JAMA Cardiol 2017;2: 775-781
20. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: Systematic review and meta-analyses. BMJ 2016;352:i717
21. Benjamin EJ, Blaha MJ, Chiuve SE, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: A report from the American Heart Association. Circulation 2017; 135:e146-e603
22. Bress AP, Tanner RM, Hess R, et al. Prevalence of eligibility criteria for the Systolic Blood Pressure Intervention Trial in US adults among excluded groups: Age , 50 years, diabetes mellitus, or a history of stroke. J Am Heart Assoc 2016;5:5
23. Bress AP, Kramer H, Khatib R, et al. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey). Circulation 2017;135: 1617-1628